Stimulation of inositol phosphate formation in cultured human retinal pigment epithelium.
Several hormones, neurotransmitters, and neuropeptides were screened for the ability to stimulate inositol phosphate formation in cultured human retinal epithelial (RPE) cells. Carbachol, vasopressin and thrombin were found to be effective. Treatment of RPE cells with all three agents produced increases in inositol monophosphate, inositol bisphosphate and inositol trisphosphate in the presence of 10 mM LiCl. Carbachol stimulated a 4-fold increase in the total of inositol phosphates at 1 mM. Studies with cholinergic antagonists showed a rank order of 4 DAMP greater than QNX greater than pirenzepine greater than methoctramine, suggesting the presence of M3 muscarinic receptors. Vasopressin gave a 2.5-fold stimulation at 10 microM. Agonists of vasopressin were also tested and gave differential responses. Studies using a V1 agonist (PIOVP) and a V2 agonist (DAVP) showed DAVP matching the level of stimulation elicited by vasopressin whereas treatment with PIOVP only reached 50% of the vasopressin response. These data suggested the presence of V2 receptors in the RPE cells. Several proteases were tested for their ability to stimulate RPE inositol phosphates. Thrombin caused a 7-fold increase in inositol phosphate formation at 1 U/ml, whereas trypsin and plasmin elicited smaller responses (approximately 2-fold). The thrombin effect was blocked by the thrombin-specific inhibitor, hirudin, but not by other protease inhibitors. Several mediators of inflammation such as bradykinin, histamine and serotonin were also tested, and they were ineffective in stimulating inositol phosphate turnover in the RPE cells.
Crook
R B
RB
Department of Ophthalmology, University of California, San Francisco 94143.
Song
M K
MK
Tong
L P
LP
Yabu
J M
JM
Polansky
J R
JR
Lui
G M
GM
D000804:Angiotensin II / Q000494:pharmacology; D001127:Arginine Vasopressin / Q000494:pharmacology; D001839:Bombesin / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D002478:Cells, Cultured; D011464:Epoprostenol / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D007294:Inositol / Q000378:metabolism; D007295:Inositol Phosphates / Q000378:metabolism*; D007700:Kinetics; D009638:Norepinephrine / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D010857:Pigment Epithelium of Eye / Q000187:drug effects / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology; D014667:Vasopressins / Q000494:pharmacology
D007295:Inositol Phosphates; D010277:Parasympathomimetics; D011480:Protease Inhibitors; D014667:Vasopressins; D000804:Angiotensin II; D001127:Arginine Vasopressin; D012701:Serotonin; D013373:Substance P; D007294:Inositol; D006632:Histamine; D002217:Carbachol; D011464:Epoprostenol; D013917:Thrombin; D001839:Bombesin; D001920:Bradykinin; D009638:Norepinephrine